Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietie stem cell transplantation in B cell malignancies [ J ]. J Hematol Oneol, 2017, 10 ( 1 ) : 35. DOI: 10.1186/s13045-017 -0405 -3.Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation...
Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital): 一种CD19抑制剂药物,由Tianjin First Center Hospital (天津市第一中心医院)公司最早进行研发,目前全球最高研发状态为临床1期,作用机制: CD19抑制剂(B淋巴细胞抗原CD19抑制剂),治疗领域: 免疫系统疾病,血
Encore: A CRISPR-edited allogeneicanti-CD19CAR-T celltherapy with aPD-1knockout (CB-010) for relapsed/refractory B cell non-Hodgkin lymphoma(r/r B-NHL):Updatedphase 1results from the ANTLER trial European Hematology Association (EHA) 2024 Hybrid Congress,June 13, 2024. ...
To address this challenge, we developed an anti-rejection CD70 CAR capable of selectively depleting activated (CD70+) host lymphocytes. We previously showed that this approach rendered allogeneic CD19 CAR T cells resistant to allorejection while also enhancing antitumor activity by endowing dual ...
T cells isolated from PBMCs were first transduced with lentivirus coding anti-CD19 CAR construct and then were knocked out for human leukocyte antigen (HLA)-A, HLA-B, class II major histocompatibility Discussion In this study, we present the very first use of off-the-shelf allogeneic CD19-...
T cells expressing chimeric antigen receptors (CARs) targeting CD19 (CD19-CARTs) have shown remarkable activity in B-cell acute lymphoblastic leukemia (B-ALL), with reported complete remission (CR) rates ranging from 61 to 93%, even in patients with multiply relapsed disease.1, 2, 3, 4, ...
The antitumor activity of CRISPR/Cas9-edited allogeneic anti-CD19 CAR-T (CAR-T19) cells was assessed in vitro, in animal models, and in patients with relapsed/refractory (R/R) acute B cell lymphoblastic leukemia (B-ALL) or diffuse large B cell lymphoma. ...
了解Tianjin First Center Hospital (天津市第一中心医院)公司的药物管线,治疗领域,技术平台,以及它的56项临床试验和2篇文献,疾病领域:血液及淋巴系统疾病,肿瘤,免疫系统疾病,技术平台:自体CAR-T,CAR-T,通用型CAR-T,药物:CAR-T (Tianjin First Center Hospital),
T. et al. Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol. Ther. 25, 949–961 (2017). Article CAS PubMed PubMed Central Google Scholar Ren, J. et al. A versatile system for rapid multiplex genome-edited ...
CD19 CAR-T candidate. While the FDA hold has since been lifted,1the event itself raises questions about what the FDA and EMA might eventually require for product clearance. Because of these uncertainties, the shiny new penny of allogeneic CAR-T cell therapies has likely lost some of its ...